DAXOR CORP: directors' dealings · United States · SEC (Form 4)

About DAXOR CORP

Daxor Corporation (ticker DXR) is a U.S.-listed micro-cap on the Nasdaq Capital Market in the United States, and it operates in a highly specialized segment of healthcare: objective blood volume measurement. For francophone investors, Daxor is best understood as a diagnostic medtech company rather than a conventional pharmaceutical business. Its core mission is to improve clinical decision-making by providing rapid, quantitative, and reproducible assessment of a patient’s blood volume status, particularly in cardiology, intensive care, sepsis, dialysis, surgery, and trauma settings. ([daxor.com](https://daxor.com/company-overview/?utm_source=openai)) The company presents a long operating history, stating that it has roughly 50 years of experience developing and commercializing its Blood Volume Analysis (BVA) technology. Daxor’s operational headquarters are in Oak Ridge, Tennessee, where it also runs a U.S.-based 20,000-square-foot manufacturing facility. That domestic footprint is strategically important in medical devices, where regulatory compliance, manufacturing quality, and hospital customer proximity matter materially. ([daxor.com](https://daxor.com/company-overview/?utm_source=openai)) At the center of the business is Daxor’s proprietary, patented, FDA-cleared diagnostic platform, the Blood Volume Analyzer. The company describes it as the only FDA-cleared diagnostic test that directly quantifies total blood volume, plasma volume, and red cell volume. Management positions the product as a way to replace subjective fluid-management guesswork with objective patient-specific data, aiming to improve outcomes and reduce costly complications. In recent communications, Daxor has emphasized a new-generation analyzer that is faster, more compact, and portable, designed to ease adoption across a broader range of clinical environments. ([daxor.com](https://daxor.com/daxor-corporation-receives-fda-clearance-for-new-rapid-lightweight-blood-volume-analysis-system/?utm_source=openai)) From a competitive standpoint, Daxor occupies a narrow but differentiated niche. Its investment case rests on clinical objectivity, intellectual-property protection, regulatory validation, and the economic value of better fluid management in high-acuity care. In 2026, the company highlighted stronger operating momentum in fiscal 2025, including growth in operating revenue, while also signaling a strategic refocus on its core diagnostic business. It further announced plans to transition its primary reporting framework from the Investment Company Act of 1940 to the Securities Exchange Act of 1934, which the market may interpret as another sign of business maturation and a stronger emphasis on the operating platform. ([daxor.com](https://daxor.com/daxor-corporation-reports-2025-fiscal-year-results-operating-revenue-up-45-net-asset-value-rises-to-9-07-per-share/?utm_source=openai)) A key recent milestone was FDA 510(k) clearance in August 2025 for the next-generation rapid, lightweight Blood Volume Analyzer. Daxor then expanded its commercial and scientific visibility with appearances at major 2026 medical conferences, including SCCM and ACC.26. For investors, these events suggest a company trying to convert regulatory progress into broader clinical adoption, stronger hospital penetration, and increased recognition in critical care and cardiology markets. ([daxor.com](https://daxor.com/daxor-corporation-receives-fda-clearance-for-new-rapid-lightweight-blood-volume-analysis-system/?utm_source=openai))